Cambridge, Mass. – November 05, 2026 -- Harbour BioMed (HKEX: 02142) has appointed Vivian Feng, a business development executive with over 16 years of biotech and pharma experience who most recently led BD at Fosun Pharma, as Senior Vice President, Head of External Collaboration. Feng will be based in Shanghai and report directly to Chief Strategy Officer Mike Patten.
Feng will oversee business development and licensing across the HBM Group
Feng will lead the antibody developer's external collaboration strategy, linking its platform, pipeline and innovation capabilities with outside partners. She will also foster synergy and information flow across HBM Group entities and its NewCos.
Her mandate includes building the processes and team capabilities for a scalable, risk-controlled external collaboration function.
Feng built a group-level BD system at Fosun Pharma covering valuation, due diligence and risk control
As General Manager of Fosun Pharma's Business Development Department, Feng led global BD initiatives. Her experience spans global licensing in and out, M&A and equity investment.
Earlier, she held BD leadership roles at Besins Healthcare Shanghai Limited, Shanghai Tenry Pharmaceutical Group and Shanghai Newsummit Pharmaceutical Group. At those companies she executed international out-licensing and co-development projects and completed more than 100 product and asset evaluations. She holds a Master of Science in Pharmaceutical Engineering from East China University of Science and Technology.
Harbour BioMed ties the hire to its global partnership expansion
Founder, Chairman and CEO Dr. Jingsong Wang said Feng's expertise in global licensing, corporate development and strategic partnership management will be instrumental as the company advances its pipeline and expands global partnerships.
Harbour BioMed builds its portfolio through internal R&D, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Feng said her goal is a "world-class external collaboration function" connecting the company's platform and science with the right partners.